Stocktoria
Apyx Medical Corp APYX
Apyx Medical Corp (APYX) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $52.8M at a -21.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.64 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.7 |
| Retained earnings / assets | -1.333 |
| EBIT / assets | -0.096 |
| Equity / liabilities | 0.285 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| APYX | Apyx Medical Corp | 5/9 | -0.11 | — | +9.9% |
| CARL | CARLSMED, INC. | 5/9 | 4.88 | — | +85.9% |
| CVRX | CVRx, Inc. | 3/9 | -15.5 | — | +10.4% |
| SI | SHOULDER INNOVATIONS, INC. | 4/9 | 7.68 | — | +49.6% |
| LNSR | LENSAR, Inc. | 2/9 | -10.17 | — | +9.2% |
| TLSI | TriSalus Life Sciences, Inc. | 4/9 | — | — | +53.4% |
| SNWV | SANUWAVE Health, Inc. | 6/9 | -19.06 | 6.3 | +35% |
About Apyx Medical Corp
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company's helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
FAQ
Is APYX financially healthy?
Apyx Medical Corp's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does APYX pay a dividend?
No, Apyx Medical Corp does not currently pay a dividend.
How profitable is APYX?
In FY2025, Apyx Medical Corp had a net margin of -21.2% and a return on equity of -75.6%.
What is the analyst price target for APYX?
The average Wall-Street price target for Apyx Medical Corp is $6.50, about 117.4% above the recent price, from 4 analysts.
Is APYX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Apyx Medical Corp: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.